View More Recent Stories

Jan 3, 2019 08:00AM Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 19, 2018 08:02AM Gilead Sciences (GILD), Scholar Rock (SRRK) Announce Pact to Develop Novel Therapies for Fibrotic Diseases
Dec 19, 2018 08:01AM Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Dec 3, 2018 04:19PM Scholar Rock Holding Corp. (SRRK) Announces Positive Opinion by EMA on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
Dec 3, 2018 04:05PM Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
Dec 3, 2018 04:05PM Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy
Nov 29, 2018 04:05PM Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
Nov 29, 2018 04:05PM Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
Nov 27, 2018 07:10AM Scholar Rock Holding Corp. (SRRK) Reports Publication of Preclinical Data on Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
Nov 27, 2018 07:00AM Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
Nov 27, 2018 07:00AM Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy
Nov 19, 2018 04:13PM Scholar Rock Holding Corp. (SRRK) Appoints Edward (Ted) Myles to Board
Nov 19, 2018 04:05PM Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
Nov 19, 2018 04:05PM Scholar Rock Announces the Addition of Edward (Ted) Myles to Its Board of Directors
Nov 9, 2018 08:03AM Scholar Rock Holding Corp. (SRRK) Reports New Preclinical Data from TGFB1 Cancer Immunotherapy Program
Nov 9, 2018 08:00AM Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade
Nov 9, 2018 08:00AM Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade
View More Recent Stories